You can view 5 more pages before signing in

CHARM Alternative trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

The CHARM-Alternative trial recruited 2028 ACE inhibitor-intolerant patients with heart failure due to left ventricular dysfunction. The patients were randomised to either candesartan or placebo.

Treatment with candesartan (an angiotensin receptor antagonist) gave clear reductions in mortality and hospital admissions.

Reference:

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386):772-6.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

CHARM Alternative trial

Related pages

Create an account to add page annotations